Amgen’s (AMGN) and UCB's drug Evenity (romosozumab), which, in long and large 24 months of clinical investigation has demonstrated superior results in reducing new vertebral, non vertebral and clinical bone fractures, has demonstrated a heart-related side effects.

At the weekend Amgen announced results from Phase 3 trials demonstrating that its product Evenity (romosozumab) met the primary and secondary endpoints of the trials, which relate to  reducing the incidence of new vertebral, non-vertebral and clinical fractures in postmenopausal women at high risk for developing bone fracture. After two years of treatment . . .